Vaccinating both boys and girls can help eliminate HPV infections

The human papillomavirus (HPV) causes, amongst other diseases, cancer of the cervix and oropharynx. A Swedish-Finnish study published in The Journal of Infectious Diseases now shows that the most oncogenic HPV types can be eliminated, but only if both girls and boys are vaccinated. Both genders will be offered vaccination in Sweden as of 2020.

The researchers began a randomized study in 2007, inviting 80,000 young people between the ages of 12 and 15 from 250 schools in 33 towns to take part. In 11 towns, both boys and girls were given HPV vaccination, in another 11 towns only girls were vaccinated, and in 11 towns the participants were vaccinated against a totally different virus (control).

General HPV screening at the age of 19 showed that the vaccination of both genders prevented HPV infections in society much more effectively than the vaccination of girls only. A gender-neutral strategy was also effective at preventing HPV infections in unvaccinated girls.

HPV was included in the Swedish vaccination program in 2012. To date, the vaccine has only been offered to girls, but in 2019 the government decided to offer it to both genders as of autumn 2020.

"Our study is unique because the entire population of the communities included in the study was invited to take part, and the choice of vaccination strategy was randomized by community," says Matti Lehtinen, researcher at the Department of Laboratory Medicine, Karolinska Institutet, who led the study. "The results have definitely influenced the decision about offering HPV vaccination to boys, which more and more countries are also deciding."

Mathematical modeling was used to calculate what the results of the randomized HPV vaccination study would mean for programs with different vaccination coverage. The improved effectiveness of vaccinating both boys and girls is particularly important if only 80 per cent or fewer of girls are vaccinated.

If only girls are offered HPV vaccination not even a school-based vaccination program will be able to eliminate the most oncogenic HPV type 16, ever. Vaccination of both boys and girls with a 75-per cent participation rate can, however, eliminate HPV 16 even in people under 30, which is the segment of the population that is mainly spreading the infection. The elimination will take place only in a few years after the vaccinated cohorts achieve these ages."

Simopekka Vänskä, docent at the Finnish Institute for Health and Welfare and the study's first author

The World Health Organization (WHO) has established the elimination of cervical cancer as a priority objective.

"The results of the randomized study of different vaccination strategies now published gives us information about how this objective could be achieved at the earliest possible time," says Lehtinen.

HPV causes a variety of cancers, above all cervical cancer in women and cancer of the oropharynx in women and men. Almost everyone has had at least one sexually transmitted HPV infection in his or her life.

The study was financed by the Academy of Finland and the Cancer Society of Finland. GlaxoSmithKline Biologicals SA financed the constituent study (data to be published separately) and was given an opportunity to check that baseline data from that study were accurately reproduced in the paper in The Journal of Infectious Diseases. The international team of co-authors has received research grants from the Swedish Cancer Society, the Ministry of Health, Government of Catalonia, and the EU's 6th and 7th Framework Programmes in the context of this study.

Source:
Journal reference:

Vänskä, S., et al. (2020) Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied. The Journal of Infectious Diseases. doi.org/10.1093/infdis/jiaa099.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study shows lack knowledge about colonoscopy among high-risk patients